Self-administration of alpha-1-antitrypsin can significantly improve patients' quality of life
Treatment of alpha-1 antitrypsin deficiency (AATD) requires lifetime administration of weekly intravenous infusions of this substance, mostly in medical facilities. The possibility of AAT application at home is being discussed. This topic was also addressed at a symposium held during the European Respiratory Society (ERS) congress, which took place in November 2019 in Madrid.
Increasing adherence and quality of life
Administering alpha-1-antitrypsin is the only available treatment option targeting the pathogenic basis of lung impairment in AATD. The need for travel and prolonged weekly waiting times at medical facilities for AAT administration at the approved dose (60 mg/kg) contributes to patient dissatisfaction and reduced adherence. Administering the infusion at home can therefore significantly improve patients' quality of life.
There is no reason to deny this possibility to AATD patients, especially since home application of medications is already possible for other rare congenital diseases such as hereditary angioedema or hemophilia. In expanding home administration of AAT, it is of course essential to first educate patients and their families, preferably through practical trials of administering the medication.
Self-administration of AAT from the perspective of doctors and patients
From the patient's perspective, home administration of AAT mainly offers greater independence, flexibility, and control of the treatment by the patient themselves. According to patient reports, administering AAT becomes very simple after training. The vast majority of patients have no issues with the administration. Access to advice and assistance is also highly valued.
From the doctor's perspective, it is crucial to select suitable patients for home treatment, considering factors such as age, laterality, motivation, the disease state of the individual, or mental abilities. Doctors are most concerned about the reduced oversight of whether the patient adheres to the treatment regimen and takes the medication regularly. However, involving patients in administering the treatment ultimately has a dual positive effect - it minimizes the burden on the healthcare system and increases patient comfort and flexibility.
(epa)
Source: Zanichelli A., Skålvoll K., Sandhaus R. A. et al. Living with alpha-1 antitrypsin deficiency: empowering patients and healthcare professionals. EMJ Respir 2019; 7 (1): 51−58.
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.
